Merck: A Speed Bump For Keytruda?

Shares of Merck are falling after the drug maker paused two enrollment in two big studies testing its cancer drug Keytruda as a treatment for multiple myleoma.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.